Kexing BiopharmEN
ENFRESPTARRUDEITNLTHKOVIID
Global Commercial Cooperation Strategy
Home / Global Business / Commercial Coop...
Global Business
Striving to become the high quality partner for China's high-quality drugs to go abroad

GLOBAL COMMERCIAL COOPERATION STRATEGY

  • PartnersTypesAssets StageIndicationsCollaboration
  • HAICHANG Bio-TechAsset PurchaseANDA(EU & China)OncologyManufacture Commercialization
  • MABPHARM MABPHARMLicense inLaunchedImmunologyCommercialization
    ( South America, Southeast Asian etc.)
  • TOT BIOPHARMLicense inLaunchedOncologyManufacture Commercialization
  • Kexing Biopharm PartnersEquity InvestmentCo-developmentPhase III clinical trialCOVID-19Equity Investment
    Co-development
    Commercialization
  • MABPHARM MABPHARMLicense inLaunchedImmunologyCommercialization (China)
  • BIORAYLicense inLaunchedImmunologyCommercialization
    (7 leading countries)
  • Tonghua DongbaoLicense inBLAImmunologyCommercialization
    (17 leading countries)
  • SouthEast UniversityJoint-LabCandidate(Exosome)--Co-development
  • Kexing Biopharm PartnersJoint-VentureCandidate(Animal Vaccine)JV
  • Chinese Academy of SciencesCo-DevelopmentCandidateSynthetic BiologyManufacture
    Commercialization
  • Shandong Academy of Agricultural SciencesCollaborationCandidateBacteriophageManufacture
    Commercialization
  • CHIATAI TLANOING PHARMACEUTICAL GROUPLicense inBLAOncologyCommercialization
    (12 leading countries)
  • Convalife PharmaceuticalsLicense inBLAOncologyCommercialization
    (6 leading countries)
  • Kexing Biopharm PartnersLicense inLaunchedOncologyCommercialization
    (1 leading countries)
  • Kexing Biopharm PartnersLicense inLaunchedNephropathyCommercialization
    (15 leading countries)